Life Sciences


Expanded solutions for seamless stem cell research


AMSBIO, a leading provider of innovative products and services for the life sciences community, announces the launch of its Expanded Stem Cell Synergy Solutions.


Over the last two decades AMSBIO has established itself as a leading international supplier of solutions for streamlined and efficient ES/iPS Cell Culture using feeder-free StemFit® media and iMatrix recombinant laminin extracellular matrices. Backed by knowledgeable support teams in the UK, USA, and Germany, AMSBIO has expanded its products and services across the entire stem cell workflow, from sourcing and growing to storing, differentiating, and manufacturing.


AMSBIO offers an extensive range of sources to facilitate cutting-edge stem cell research. including fresh tissues covering a wide range of donors and disease states, cell lines and a custom pluripotent stem cell (iPSC) generation service. By segmenting the stem cell workflow, AMSBIO supports researchers by simplifying the procurement process and providing valuable guidance at each stage of your stem cell research.


Discover everything you need for stem cell culture with superior expansion rates whilst maintaining genetic stability, as well as reliable solutions for long-term cryopreservation. In addition, AMSBIO offers an extensive range of leading-edge cryopreservation solutions that guarantee the integrity of


your cells. For efficient stem cell differentiation toward specific cell lineages from PSCs, AMSBIO offers a specially curated differentiation product range.


To seamlessly transition your research to deployment in clinical applications, AMSBIO offer a suite of GMP-compliant manufacturing products and services trusted by a growing group of leading pharma and biotech organisations. More information online: ilmt.co/PL/NAkz


62067pr@reply-direct.com Cutting-edge genomic array advances global pharmacogenomic research


Thermo Fisher Scientific responds to the demand for a more inclusive representation of the human genome with the introduction of its latest and most diverse genomic array, the AxiomTM PangenomiX Array*. Built upon the first draft of the pangenome, which incorporated full genetic blueprints from 47 individuals worldwide, this high-throughput microarray offers unparalleled coverage for population-scale disease investigations and pharmacogenomic research.


The prevailing large-scale genomic datasets primarily rely on European and Caucasian cohorts, limiting the understanding of genetic variations in other populations, including African, Asian, and mixed populations. The PangenomiX Array aims to address this gap by providing comprehensive genomic insights across diverse ethnicities, supporting proactive healthcare models emphasising the role of genetics in disease risk and drug response.


Distinguishing itself as the only research solution combining four assays in a single test - SNP genotyping, whole genome copy number


variant detection, fixed copy number discovery, blood, and HLA typing - the PangenomiX Array facilitates advancements in disease risk and detection, population-scale research programs, ancestry testing, wellness assessments, drug efficacy trials, and drug development endeavours.


The array incorporates clinically relevant pharmacogenomic markers and pathogenic variants, offering researchers improved whole-genome imputation and a high degree of diversity for testing across various ethnic backgrounds. Already utilised in the analysis of nearly half a million ethnically diverse samples at a prominent US biobank, the PangenomiX Array contributes to inclusive research studies focused on preventing, diagnosing, and treating diseases.


Kim Caple, President of Genetic Sciences at Thermo Fisher Scientific, commented: “The PangenomiX Array marks a significant stride in diversifying genomic datasets, propelling population-scale disease testing to unprecedented levels. This development holds long-term implications for our understanding of human disease, drug development, pharmacogenomics, and ancestry. With its extensive coverage, cost-effectiveness, accuracy, and reproducibility, the array builds on our three decades of dedicated microarray research, aiming to empower research that enhances people’s longevity and well-being.”


More information online: ilmt.co/PL/A6k1 61777pr@reply-direct.com


Optimising liquid handling for NGS-based laboratory developed tests


SPT Labtech, a global leader in automated life science instrumentation, has introduced significant upgrades to its firefly® genomics liquid handling platform, catering specifically to the demands of Laboratory Developed Tests (LDTs) involved in Next-Generation Sequencing (NGS) library preparation.


Launched in February 2022, the firefly platform has been instrumental in revolutionising NGS library preparation for genomics researchers. By consolidating precise pipetting, non-contact reagent dispensing, shaking, and incubating into a compact benchtop design, firefly automates repetitive liquid handling tasks, elevating laboratory throughput and enhancing the quality of output data.


Key to its efficiency is the integrated positive displacement non-contact dispensing capability, requiring significantly less reagent dead volume compared to competing automation solutions. The firefly platform not only ensures fast and accurate liquid handling but also provides access to SPT Labtech’s dedicated reliance® service and support team for sustained high-throughput operations and assistance in new protocol development.


Recognising the critical needs of clinical laboratories offering LDTs, firefly’s recent enhancements focus on delivering rapid setup, minimised downtime, versatility, robustness, and a user-friendly, consistent operation. Some noteworthy features include a compact design that maximises functionality while conserving premium footprint, user access control with individual accounts and set privileges, easy-to-use protocol creation through an intuitive visual interface, and open-access software that supports unrestricted versions and compatibility with any computer.


These upgrades come at a crucial time, addressing the escalating complexity of LDTs and alleviating the heightened operational burden they impose. Laboratories adopting firefly benefit not only from advanced liquid handling capabilities but also from a holistic solution designed to meet the stringent demands of regulated environments.


More information online: ilmt.co/PL/kAyk 61943pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48